Absorption of high dose furosemide (frusemide) in congestive heart failure.

abstract：:The pharmacokinetics of gentamicin were studied after total hip joint arthroplasties in 2 groups of 10 patients. The prosthesis was performed in the first group with 'Palacos R plus gentamicin' (normal viscosity), manufactured by Schering, and in the second group with 'Cerafix genta R' (low viscosity) manufactured by ...

journal_title：Clinical pharmacokinetics

authors： Bunetel L,Segui A,Cormier M,Langlais F

更新日期：1990-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequen...

journal_title：Clinical pharmacokinetics

authors： González-Sales M,Barrière O,Tremblay PO,Nekka F,Mamputu JC,Boudreault S,Tanguay M

更新日期：2015-03-01 00:00:00

abstract：:5-Fluorouracil, first introduced as a rationally synthesized anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the colon, breast and skin. This drug, an analogue of the naturally occurring pyrimidine uracil, is metabolised via the same metab...

journal_title：Clinical pharmacokinetics

authors： Diasio RB,Harris BE

更新日期：1989-04-01 00:00:00

abstract：:The ability of a wide variety of anionic, cationic, and neutral drugs to bind in a reversible manner to plasma proteins has long been recognised. Non-steroidal anti-inflammatory drugs (NSAIDs) are distinguished as a class by the high degree to which they bind to plasma protein. Plasma protein binding properties are pr...

journal_title：Clinical pharmacokinetics

authors： Lin JH,Cocchetto DM,Duggan DE

更新日期：1987-06-01 00:00:00

abstract：:Models of tolerance are commonly derived on empirical grounds, because of lack of knowledge about the mechanism of tolerance or because of the difficulty of appropriately simplifying complex physiological processes. The present study was performed to evaluate the interchangeability of tolerance models used in the lite...

journal_title：Clinical pharmacokinetics

authors： Gårdmark M,Brynne L,Hammarlund-Udenaes M,Karlsson MO

更新日期：1999-02-01 00:00:00

abstract：:Sevoflurane is a comparatively recent addition to the range of inhalational anaesthetics which has been recently released for clinical use. In comparison to older inhalational agents such as isoflurane or halothane, the most important property of sevoflurane is its low solubility in the blood. This results in a more r...

journal_title：Clinical pharmacokinetics

authors： Behne M,Wilke HJ,Harder S

更新日期：1999-01-01 00:00:00

abstract：INTRODUCTION:Bruton tyrosine kinase (BTK) is a key component of B-cell receptor signalling, critical for cell proliferation. Acalabrutinib, a selective, covalent BTK inhibitor, recently received an accelerated approval in relapsed/refractory mantle cell lymphoma. This analysis characterized the population pharmacokinet...

journal_title：Clinical pharmacokinetics

authors： Edlund H,Lee SK,Andrew MA,Slatter JG,Aksenov S,Al-Huniti N

更新日期：2019-05-01 00:00:00

abstract：:Drugs from a wide range of pharmacological classes are commonly given to women in childbirth, either for a maternal effect or a fetal/neonatal effect. A number of striking physiological and biochemical changes occur during labour and delivery that might alter drug kinetics. The rate of drug absorption from the gastroi...

journal_title：Clinical pharmacokinetics

authors： Nation RL

更新日期：1980-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:NXY-059 (disufenton sodium, Cerovive, a nitrone with neuroprotective and free radical trapping properties (in experimental stroke) is under development for the treatment of acute stroke. The objectives of this study were to develop a population pharmacokinetic model for NXY-059 in acute stroke...

journal_title：Clinical pharmacokinetics

authors： Jönsson S,Cheng YF,Edenius C,Lees KR,Odergren T,Karlsson MO

更新日期：2005-01-01 00:00:00

abstract：:Acute coronary syndromes (ACS) remain life-threatening disorders associated with high morbidity and mortality, despite advances in treatment over the last decade. Adenosine diphosphate-induced platelet activation via P2Y(12) receptors plays a pivotal role in the pathophysiology of ACS. The current standard of treatmen...

journal_title：Clinical pharmacokinetics

authors： Teng R

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:A population pharmacokinetic (PK) protein-binding model was developed to (1) predict free mycophenolic acid (fMPA) based on total MPA (tMPA) concentrations in renal transplant patients, to establish the therapeutic range of fMPA through pharmacokinetic-pharmacodynamic studies; and (2) provide a guideline for...

journal_title：Clinical pharmacokinetics

authors： Colom H,Andreu F,van Gelder T,Hesselink DA,de Winter BCM,Bestard O,Torras J,Cruzado JM,Grinyó JM,Lloberas N

更新日期：2018-07-01 00:00:00

abstract：:The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment. Systemic exposure to the drugs or their main metabolites was determined dur...

journal_title：Clinical pharmacokinetics

authors： Lévi F,Karaboué A,Etienne-Grimaldi MC,Paintaud G,Focan C,Innominato P,Bouchahda M,Milano G,Chatelut E

更新日期：2017-02-01 00:00:00

abstract：:The plasma protein binding of drugs, particularly those that are highly bound, may have significant clinical implications. Although protein binding is a major determinant of drug action, it is only one of a myriad of factors that influence drug disposition. The extent of protein binding is a function of drug and prote...

journal_title：Clinical pharmacokinetics

authors： Grandison MK,Boudinot FD

更新日期：2000-03-01 00:00:00

abstract：:Platelets contribute significantly to arterial-occlusive thrombosis, one of the major causes of death and disease throughout the world. Consequently, inhibiting platelet function is a potentially important therapeutic goal. Among agents that inhibit platelet function, ticlopidine shows a wide spectrum of antiplatelet ...

journal_title：Clinical pharmacokinetics

authors： Desager JP

更新日期：1994-05-01 00:00:00

abstract：:Carboplatin shares some of the therapeutic advantages of cisplatin, but without a significant incidence of the dose-limiting neurotoxicity and nephrotoxicity which is experienced with cisplatin. However, its use is associated with dose-limiting bone marrow suppression. Carboplatin is present in the blood as 3 distinct...

journal_title：Clinical pharmacokinetics

authors： Duffull SB,Robinson BA

更新日期：1997-09-01 00:00:00

abstract：:The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state ...

journal_title：Clinical pharmacokinetics

authors： Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

更新日期：1985-11-01 00:00:00

abstract：:Since up to 90% of a theophylline dose is biotransformed, drugs influencing microsomal enzyme systems in the liver may affect the elimination of theophylline. Other integrated mechanisms (e.g. hepatic uptake) may also be altered by concurrent administration of other drugs. Whatever the mechanism, the interaction may b...

journal_title：Clinical pharmacokinetics

authors： Jonkman JH,Upton RA

更新日期：1984-07-01 00:00:00

abstract：:Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations we...

journal_title：Clinical pharmacokinetics

authors： Uribe M,Summerskill WH,Go VL

更新日期：1982-09-01 00:00:00

abstract：:Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. It is a lipophilic molecule, with its bioavailability dependent on food, bile and other interacting factors. Cyclosporin is extensively metabolised in the liver by the cytochrome P450 3A system, which is...

journal_title：Clinical pharmacokinetics

authors： Fahr A

更新日期：1993-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The likelihood of detecting a therapeutic signal of an effective drug for schizophrenia is impeded by a high placebo effect and by high dropout of patients. Several unsuccessful trials of schizophrenia, at least partly due to highly variable placebo effects, have indicated the necessity for a ...

journal_title：Clinical pharmacokinetics

authors： Pilla Reddy V,Kozielska M,Johnson M,Suleiman AA,Vermeulen A,Liu J,de Greef R,Groothuis GM,Danhof M,Proost JH

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies. This study examined the population pharmacokinetics of oral labetalol ...

journal_title：Clinical pharmacokinetics

authors： Fischer JH,Sarto GE,Hardman J,Endres L,Jenkins TM,Kilpatrick SJ,Jeong H,Geller S,Deyo K,Fischer PA,Rodvold KA

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Inolimomab, a monoclonal antibody against interleukin (IL)-2Ralpha (CD25) has shown promising results in the treatment of corticosteroid-resistant acute graft-versus-host disease (GvHD). The objective of the present study was to characterise the pharmacokinetic and pharmacodynamic properties of...

journal_title：Clinical pharmacokinetics

authors： Dartois C,Freyer G,Michallet M,Hénin E,You B,Darlavoix I,Vermot-Desroches C,Tranchand B,Girard P

更新日期：2007-01-01 00:00:00

abstract：:The pharmacokinetics and cardiovascular effects of the calcium entry blocker nisoldipine (10 mg twice daily) were studied in 6 patients with renal failure (creatinine clearance 23 +/- 9 ml/min) and 6 healthy control subjects after a single dose and 1 week of oral administration. No significant differences in eliminati...

journal_title：Clinical pharmacokinetics

authors： van Harten J,Burggraaf J,van Brummelen P,Breimer DD

更新日期：1989-01-01 00:00:00

abstract：:Antipsychotics may cause serious adverse cardiovascular effects, including prolonged QT interval and sudden death. This review considers antipsychotic-induced cardiovascular events from three perspectives: high-risk drugs, high-risk individuals and high-risk drug interactions. Pharmacokinetic drug interactions involvi...

journal_title：Clinical pharmacokinetics

authors： Brown CS,Farmer RG,Soberman JE,Eichner SF

更新日期：2004-01-01 00:00:00

abstract：:Haloperidol has been used extensively for the treatment of psychotic disorders, and it has been suggested that the monitoring of plasma haloperidol concentration is clinically useful. Different assay methodologies have been used in research and clinical practice to examine the relationship between response and plasma ...

journal_title：Clinical pharmacokinetics

authors： Froemming JS,Lam YW,Jann MW,Davis CM

更新日期：1989-12-01 00:00:00

abstract：:Pancuronium is frequently used in coronary artery surgery, but its pharmacokinetics in these patients are still unknown. It is possible that dopamine, administered to prevent renal impairment induced by the surgery, might promote the elimination of pancuronium. Therefore, the pharmacokinetics of a bolus dose of pancur...

journal_title：Clinical pharmacokinetics

authors： Wierda JM,van der Starre PJ,Scaf AH,Kloppenburg WD,Proost JH,Agoston S

更新日期：1990-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer. The aim of this phase II, crossover, bioequivalence study was to compare the pharmacokinetics (primary objective) and tolerability (secondary objective) of tegafur-uracil (UFT) given as three daily doses (tid, r...

journal_title：Clinical pharmacokinetics

authors： Etienne-Grimaldi MC,François E,Cardot JM,Renée N,Douillard JY,Gamelin E,Bennouna J,Château Y,Milano G

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Enzyme replacement therapy (ERT) is currently the standard treatment for patients with Gaucher disease type I (GD1), but the pharmacokinetics have hardly been studied. This study aimed to quantify in vivo enzyme activity in peripheral leukocytes from patients receiving long-term treatment with imiglucerase o...

journal_title：Clinical pharmacokinetics

authors： Gras-Colomer E,Martínez-Gómez MA,Moya-Gil A,Fernandez-Zarzoso M,Merino-Sanjuan M,Climente-Martí M

更新日期：2016-09-01 00:00:00

abstract：:The various components required for individualising clinical drug dosage regimens are reviewed, including a study of 3 types of fitting procedures, 2 types of gentamicin pharmacokinetic model and the utility of D-optimal times for obtaining serum gentamicin concentrations. The combination of the current Bayesian fitti...

journal_title：Clinical pharmacokinetics

authors： Jelliffe RW,Iglesias T,Hurst AK,Foo KA,Rodriguez J

更新日期：1991-12-01 00:00:00

abstract：:For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information. However, now that this information is available, it is appropriate to examine current recommendations for prophylaxis and treatment. In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine an...

journal_title：Clinical pharmacokinetics

authors： White NJ

更新日期：1985-05-01 00:00:00